CSTL

Castle Biosciences (CSTL)

About Castle Biosciences (CSTL)

Castle Biosciences, Inc.is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett’s esophagus, uveal melanoma, and in the treatment of mental health conditions. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

Details

Daily high
$39.53
Daily low
$38.24
Price at open
--
52 Week High
$40.61
52 Week Low
$14.59
Market cap
1.1B
Dividend yield
0.00%
Volume
50
Avg. volume
472,665
P/E ratio
-86.38

Castle Biosciences News

Details

Daily high
$39.53
Daily low
$38.24
Price at open
--
52 Week High
$40.61
52 Week Low
$14.59
Market cap
1.1B
Dividend yield
0.00%
Volume
50
Avg. volume
472,665
P/E ratio
-86.38